De Villartay J P, Griscelli C, Fischer A
Eur J Immunol. 1986 Feb;16(2):117-22. doi: 10.1002/eji.1830160202.
The transplantation of T cell-depleted HLA-haploidentical bone marrow can correct the severe combined immunodeficiency disease (SCID) caused by the inherited absence of T lymphocytes. Despite a different environment, no severe graft-vs.-host reaction occurred and engrafted T lymphocytes became functional. We have studied tolerance of engrafted T lymphocytes to donor and host HLA antigens in four SCID patients who have been transplanted with bone marrow from one of their HLA-haploidentical parents. Graft-vs.-host reaction was prevented by T cell depletion of infused bone marrow using E rosetting and by in vivo administration of cyclosporine A. Subsequent to bone marrow transplantation (BMT), the engrafted T lymphocytes were shown to be unresponsive in vitro towards host cells collected prior to BMT. Generally, this tolerance could not be explained by a suppressive mechanism. Nevertheless, in one patient suppressive cells were found transiently. In contrast to the early appearance of a tolerance towards host, a reactivity of engrafted donor cells towards donor was always observed within the first 300 days post-grafting. This autoreactivity was mediated by T cells of donor origin and its targets were HLA class II molecules (at least HLA-DR and DQ). The progressive disappearance of this autoreactivity was correlated with the engraftment of Ia-positive cells (monocytes plus B lymphocytes) of donor origin and the achievement of complete immunological reconstitution. In the patient showing the strongest autoreactivity, a donor-specific T cell line has been grown which was shown to specifically inhibit the proliferative response of donor lymphocytes. Concomittantly, the immunological reconstitution remains poor in this patient. These data suggest that tolerance to HLA class II molecules is dependent on the presence of the relevant HLA class II molecule-expressing cells allowing the elimination or the suppression of T lymphocytes specifically directed at these molecules.
移植去除T细胞的HLA单倍型相合骨髓可纠正因遗传性T淋巴细胞缺乏所致的重症联合免疫缺陷病(SCID)。尽管环境不同,但未发生严重的移植物抗宿主反应,植入的T淋巴细胞发挥了功能。我们研究了4例接受来自HLA单倍型相合父母之一的骨髓移植的SCID患者中植入的T淋巴细胞对供体和宿主HLA抗原的耐受性。通过用E花环法去除输注骨髓中的T细胞以及体内给予环孢素A预防移植物抗宿主反应。骨髓移植(BMT)后,植入的T淋巴细胞在体外对BMT前采集的宿主细胞无反应。一般来说,这种耐受性无法用抑制机制来解释。然而,在1例患者中短暂发现了抑制性细胞。与对宿主耐受性的早期出现相反,在移植后的前300天内总是观察到植入的供体细胞对供体有反应性。这种自身反应性由供体来源的T细胞介导,其靶标是HLA II类分子(至少HLA-DR和DQ)。这种自身反应性的逐渐消失与供体来源的Ia阳性细胞(单核细胞加B淋巴细胞)的植入以及完全免疫重建的实现相关。在自身反应性最强的患者中,培养出了一种供体特异性T细胞系,该细胞系被证明能特异性抑制供体淋巴细胞的增殖反应。与此同时,该患者的免疫重建仍然较差。这些数据表明,对HLA II类分子的耐受性取决于表达相关HLA II类分子的细胞的存在,这些细胞可允许消除或抑制特异性针对这些分子的T淋巴细胞。